| Drug Type CAR-T | 
| Synonyms- | 
| Target | 
| Action inhibitors | 
| Mechanism CD56 inhibitors(Neural cell adhesion molecule 1 inhibitors), Immunologic cytotoxicity, T lymphocyte replacements | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePhase 2 | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Extranodal NK-T-Cell Lymphoma | Phase 2 | China  | 01 May 2023 | 





